Vanda Pharmaceuticals Inc. / Fundamentals
Income statement
- Net revenue
€174.57M - Cost of goods sold
€7.43M - Gross profit
€120.52M - SG&A expenses
€164.35M - R&D expenses
€80.92M - EBITDA
-€74.61M - D&A
€4.22M - EBIT
-€89.52M - Interest expenses
€0.00 - EBT
-€72.93M - Tax expenses
-€15.49M - Net income
-€57.43M
Cash flow statement
- Net deferred tax
-€17.82M - Non-cash items
€15.24M - Changes in working capital
-€7.66M - Operating cash flow
-€55.60M - Capex
€952.38K - Other investing cash flow
€0.00 - Net investing cash flow
€38.34M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
-€350.92K - Other financing cash flow
-€785.07K - Net financing cash flow
-€1.50M - Foreign exchange effects
€42.04K - Net change in cash
€7.59M - Cash at end of period
€0.00 - Free cash flow
-€54.64M
Balance sheet
- Cash and cash equivalents
€69.48M - Cash and short-term investments
€279.32M - Total receivables
€38.60M - Inventory
€1.86M - Other current assets
€19.06M - Total current assets
€338.84M - Property, plant & equipment
€10.70M - Goodwill
€0.00 - Intangible assets
€94.89M - Long-term investments
€0.00 - Other non-current assets
€8.25M - Total non-current assets
€197.19M - Total assets
€536.03M - Accounts payable
€0.00 - Short-term debt
€0.00 - Other current liabilities
€104.24M - Total current liabilities
€104.24M - Long-term debt
€5.97M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€8.55M - Total non-current liabilities
€14.52M - Total liabilities
€118.76M - Common stock
€50.62K - Retained earnings
-€198.19M - Other equity
€339.77K - Total equity
€417.27M - Total liabilities and shareholders' equity
€536.03M
Company information
- Market capitalization
€240.28M - Employees
368 - Enterprise Value
€165.48M
Company ratios
- Gross margin
-
69.0% Much better than peer group: -174.4% - EBITDA margin
-
-42.7% Much worse than peer group: 148,840.9% - EBIT margin
-
-51.3% Much worse than peer group: 157,275.2% - EBT margin
-
-41.8% Much worse than peer group: 160,205.4% - Net margin
-
-32.9% Much worse than peer group: 160,232.5% - ROE
-
-13.8% Even with peer group: -11.4% - ROA
-
-10.7% Better than peer group: -24.6% - Asset turnover
-
32.6% Better than peer group: 21.0% - FCF margin
-
-32.4% Much worse than peer group: 153,620.6% - FCF yield
-23.5% - Efficiency ratio
142.7% - Net sales per employee
-
€474.39K - Net income per employee
-
-€156.07K